PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Lewy Body Disorders.

Abstract Dementia syndromes associated with Lewy bodies are subdivided into dementia with Lewy bodies (DLB), an underdiagnosed cause of dementia in the elderly, and Parkinson disease with dementia (PDD), cognitive impairment appearing in people diagnosed with Parkinson disease. Their neuropathologic substrates are the widespread distribution of aggregates of the protein α-synuclein in neurons in cortical brain regions, accompanied by variable Alzheimer pathology. Clinical features of DLB and PDD include distinctive changes in cognition, behavior, movement, sleep, and autonomic function. Diagnostic criteria for DLB and PDD incorporate these features. Current treatment options for DLB and PDD are symptomatic.
PMID
Related Publications

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Significance of brain lesions in Parkinson disease dementia and Lewy body dementia.

Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies.

Imaging amyloid deposition in Lewy body diseases.

Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia.

Authors

Mayor MeshTerms
Keywords

Dementia

Diagnosis

Lewy body

Management

α-synuclein

Journal Title neurologic clinics
Publication Year Start




PMID- 28410662
OWN - NLM
STAT- In-Process
DA  - 20170415
LR  - 20170415
IS  - 1557-9875 (Electronic)
IS  - 0733-8619 (Linking)
VI  - 35
IP  - 2
DP  - 2017 May
TI  - Lewy Body Disorders.
PG  - 325-338
LID - S0733-8619(17)30004-X [pii]
LID - 10.1016/j.ncl.2017.01.004 [doi]
AB  - Dementia syndromes associated with Lewy bodies are subdivided into dementia with 
      Lewy bodies (DLB), an underdiagnosed cause of dementia in the elderly, and
      Parkinson disease with dementia (PDD), cognitive impairment appearing in people
      diagnosed with Parkinson disease. Their neuropathologic substrates are the
      widespread distribution of aggregates of the protein alpha-synuclein in neurons
      in cortical brain regions, accompanied by variable Alzheimer pathology. Clinical 
      features of DLB and PDD include distinctive changes in cognition, behavior,
      movement, sleep, and autonomic function. Diagnostic criteria for DLB and PDD
      incorporate these features. Current treatment options for DLB and PDD are
      symptomatic.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Galasko, Douglas
AU  - Galasko D
AD  - Department of Neurosciences, University of California, San Diego, 9500 Gilman
      Drive, La Jolla, CA 92093-0948, USA. Electronic address: [email protected]
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Neurol Clin
JT  - Neurologic clinics
JID - 8219232
OTO - NOTNLM
OT  - Dementia
OT  - Diagnosis
OT  - Lewy body
OT  - Management
OT  - alpha-synuclein
EDAT- 2017/04/16 06:00
MHDA- 2017/04/16 06:00
CRDT- 2017/04/16 06:00
AID - S0733-8619(17)30004-X [pii]
AID - 10.1016/j.ncl.2017.01.004 [doi]
PST - ppublish
SO  - Neurol Clin. 2017 May;35(2):325-338. doi: 10.1016/j.ncl.2017.01.004.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>